CA
NZ
UK
AU
IND
US
This move aligns with the company’s strategy to draw in talent essential for advancing its precision medicine initiatives in oncology, potentially boosting employee retention and company performance. As the stock options vest over four years, this structure encourages long-term commitment from new hires, important …
Nxera Pharma conducted its Q2 2026 earnings call on August 7, focusing heavily on growth strategies stemming from its commitment to innovation. The leadership team highlighted efforts to enhance its product pipeline, emphasizing a long-term vision to capitalize on emerging market opportunities. This shift …
This adjustment coincides with a shift from traditional debt obligations to revenue-linked payments, allowing the company to potentially enhance its financial flexibility and fund growth initiatives. The announcement marks an essential pivot in Verastem's financing strategy, coming at a time when the company needs …
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) achieved $254.6 million in worldwide sales during the second quarter of 2026, reflecting a 6% improvement from $240.7 million in the same quarter last year. This performance surpassed analyst expectations, as the reported earnings per share (EPS) came …
BioAffinity Technologies announced a 216% year‑over‑year surge in CyPath Lung test volume for the second quarter of 2026, delivering 1,097 reports in the first six months and propelling quarterly revenue to $1.5 million, a 19% rise from the prior year. The expansion of physician …
The company also narrowed its net loss to $59.2 million and generated $54.6 million of free cash flow. Sector peers GDRX rose 1.9% and TDOC advanced 6.9%, while CERT was little changed.
Embecta Corp (NASDAQ: EMBC) reduced its revolving credit facility from $500 million to $310 million, a 38% contraction, while simultaneously repaying $53 million of debt in the quarter. The move compresses the company’s borrowing capacity but also shrinks its leverage, a material shift that …
Pharvaris NV has received significant attention after Claude AI announced a 4% position in the company, enhancing its visibility amid a critical drug trial. Claimed as a breakout biotech, Pharvaris is known for its single drug targeting hereditary angioedema, a rare disease causing sudden …
Treace Medical Concepts (NASDAQ: TMCI) delivered second‑quarter results that showed a continued narrowing of its loss profile. Operating expenses were reduced to $50.6 million, underscoring the firm’s ongoing cost‑discipline initiatives.
Atossa Therapeutics (NASDAQ: ATOS) announced a registered direct offering that could generate as much as $16.5 million, roughly 69 % of its $24 million market value. The combination of a substantial capital influx and a strong earnings beat offers investors a rare double‑edge of …
Please wait processing your request...